S. E. Poduslo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
S. E. Poduslo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
R. Huang
Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia
5 shared publicationsJ. Huang
The Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA, United States
3 shared publicationsR Huang
Institute of Molecular Medicine and Genetics, Augusta, Georgia, USA
3 shared publicationsI. Lanham
Medical College of Georgia
2 shared publicationsA. D. Winkie
Medical College of Georgia
1 shared publication- Avron Spiro
Department of Psychiatry, Boston University, Chobanian & Avedisian School of Medicine
1 shared publication
Latest Publications
- 21 December 2009
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 153B (1) , 114-119
A genome screen of successful aging without cognitive decline identifies LRP1B by haplotype analysis
Successful aging without cognitive decline (SA) is apparent in those who escape age-related illnesses, such as cardiovascular disease and dementia. To determine whether there are protective genotypes that increase the probability of successful cognitive aging, a genome-wide screen was conducted on subjects who were 85 years of older, had MMSE scores >26, and had no major illnesses. SNP 500K microarrays were used. The data from the microarrays was analyzed versus that from Alzheimer's patients. Three SNPs in the gene for the low density lipoprotein receptor-related protein 1B (LRP1B) had significant P values, after Bonferroni correction. Additional SNPs were analyzed in this very large gene. Haplotypes in intron 18 were significant for successful aging versus Alzheimer's patients; those haplotypes were not significant when Alzheimer's patients versus CEPH controls were analyzed. These results suggest that haplotypes in the gene LRP1B are significant/protective for successful aging without cognitive decline.
- 21 December 2009
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 153B (1) , 114-119
A genome screen of successful aging without cognitive decline identifies LRP1B by haplotype analysis
Successful aging without cognitive decline (SA) is apparent in those who escape age-related illnesses, such as cardiovascular disease and dementia. To determine whether there are protective genotypes that increase the probability of successful cognitive aging, a genome-wide screen was conducted on subjects who were 85 years of older, had MMSE scores >26, and had no major illnesses. SNP 500K microarrays were used. The data from the microarrays was analyzed versus that from Alzheimer's patients. Three SNPs in the gene for the low density lipoprotein receptor-related protein 1B (LRP1B) had significant P values, after Bonferroni correction. Additional SNPs were analyzed in this very large gene. Haplotypes in intron 18 were significant for successful aging versus Alzheimer's patients; those haplotypes were not significant when Alzheimer's patients versus CEPH controls were analyzed. These results suggest that haplotypes in the gene LRP1B are significant/protective for successful aging without cognitive decline.
- 6 February 2009
- Published by Elsevier in Neuroscience Letters
- Vol. 450 (3) , 344-346
The frequency of the TRPC4AP haplotype in Alzheimer's patients
- 6 February 2009
- Published by Elsevier in Neuroscience Letters
- Vol. 450 (3) , 344-346
The frequency of the TRPC4AP haplotype in Alzheimer's patients
- 30 April 2008
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 150B (1) , 50-55
Genome screen of late‐onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis
Alzheimer's disease is a complex progressive neurodegenerative disorder with profound cognitive decline. Multiple susceptibility genetic variants have been identified with equivocal replication. While rare, collections of extended pedigrees with multiple affected family members are invaluable for genome‐wide screens. We have used two extended pedigrees, having 14–15 siblings with four to five affected late‐onset Alzheimer's disease patients in each, to identify the gene, transient receptor potential cation channel, subfamily C, member 4 associated protein (TRPC4AP), on chromosome 20q11.22, as relevant for the disease. Multiple significant SNPs in this gene were found with the initial genome scan (after Bonferroni correction). Additional SNPs were assessed in the families and in the controls which were also significant by haplotype analysis. Moreover, 36% of the patients' haplotypes in our collection of late‐onset patients had the same haplotype. These results suggest that TRPC4AP is involved with the disease in these late‐onset Alzheimer's families. The results also confirm the use of the genome‐wide association study for identifying new genetic variants of complex diseases.
- 30 April 2008
- Published by Wiley in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Vol. 150B (1) , 50-55
Genome screen of late‐onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis
Alzheimer's disease is a complex progressive neurodegenerative disorder with profound cognitive decline. Multiple susceptibility genetic variants have been identified with equivocal replication. While rare, collections of extended pedigrees with multiple affected family members are invaluable for genome‐wide screens. We have used two extended pedigrees, having 14–15 siblings with four to five affected late‐onset Alzheimer's disease patients in each, to identify the gene, transient receptor potential cation channel, subfamily C, member 4 associated protein (TRPC4AP), on chromosome 20q11.22, as relevant for the disease. Multiple significant SNPs in this gene were found with the initial genome scan (after Bonferroni correction). Additional SNPs were assessed in the families and in the controls which were also significant by haplotype analysis. Moreover, 36% of the patients' haplotypes in our collection of late‐onset patients had the same haplotype. These results suggest that TRPC4AP is involved with the disease in these late‐onset Alzheimer's families. The results also confirm the use of the genome‐wide association study for identifying new genetic variants of complex diseases.
- 29 February 2008
- Published by Springer Nature in Neurochemical Research
- Vol. 34 (1) , 23-28
Cluster Analysis of Risk Factor Genetic Polymorphisms in Alzheimer’s Disease
Multiple genetic variants may contribute to the risk of developing Alzheimer’s disease. We have analyzed polymorphisms in 9 genes to determine whether particular combinations would contribute to this risk. The genes were APOE, LDLr, CST3, CTSD, TNF, BACE1, MAPT, STH, eNOS, and TFCP2. Three risk groups for the disease were identified. Risk group I was younger, was heterozygous for the CST3 (GA), CTSD2936 (AG), TNF -308 (AG) genetic variants. Risk group II was older, was homozygous for the −427 APOE promoter polymorphism (TT), and heterozygous for the MAPT deletion and for the STH variant (QR). Group III had both the youngest and oldest subjects, were heterozygous for the −863 (AC) and −1031 (CT) TNF promoter polymorphisms. All three groups carried the APOE 4 allele and were heterozygous for both BACE1 polymorphisms. The control groups were carriers of the APOE 3 allele and were homozygous for the BACE1 genetic variants.
- 29 February 2008
- Published by Springer Nature in Neurochemical Research
- Vol. 34 (1) , 23-28
Cluster Analysis of Risk Factor Genetic Polymorphisms in Alzheimer’s Disease
Multiple genetic variants may contribute to the risk of developing Alzheimer’s disease. We have analyzed polymorphisms in 9 genes to determine whether particular combinations would contribute to this risk. The genes were APOE, LDLr, CST3, CTSD, TNF, BACE1, MAPT, STH, eNOS, and TFCP2. Three risk groups for the disease were identified. Risk group I was younger, was heterozygous for the CST3 (GA), CTSD2936 (AG), TNF -308 (AG) genetic variants. Risk group II was older, was homozygous for the −427 APOE promoter polymorphism (TT), and heterozygous for the MAPT deletion and for the STH variant (QR). Group III had both the youngest and oldest subjects, were heterozygous for the −863 (AC) and −1031 (CT) TNF promoter polymorphisms. All three groups carried the APOE 4 allele and were heterozygous for both BACE1 polymorphisms. The control groups were carriers of the APOE 3 allele and were homozygous for the BACE1 genetic variants.
- 27 February 2007
- Published by Elsevier in Neuroscience Letters
- Vol. 414 (1) , 51-56
APOE genotypes in African American female multiple sclerosis patients
- 27 February 2007
- Published by Elsevier in Neuroscience Letters
- Vol. 414 (1) , 51-56
APOE genotypes in African American female multiple sclerosis patients
- 9 February 2007
- Published by BMJ in Journal of Medical Genetics
- Vol. 44 (2) , e66
Genetic variants in brain-derived neurotrophic factor associated with Alzheimer’s disease
Background: Alzheimer’s disease is complex, with variants in multiple genes contributing to interactions increasing risk for the disease. Brain-derived neurotrophic factor (BDNF) promotes neuronal survival and modulates hippocampal-dependent memory. Methods: We examined 11 SNPs that spanned the gene on chromosome 11p14 in 220 Alzheimer’s patients and 128 control spouses. Results: Not all of the SNPs were informative, due to minor allele frequencies of Conclusion: The combination of the diplotypes for three SNPs exhibited significant p values for Alzheimer’s APOE 4 non-carriers. The two SNPs (rs11030104 and rs2049045) are found between exons VI and VII, while the Val66Met polymorphism is located in the coding exon VIII; the total distance for the three SNPs is 14308 bp. Whether the SNPs are involved with alternative splicing of the VII/VIII transcript is of considerable interest.
- 9 February 2007
- Published by BMJ in Journal of Medical Genetics
- Vol. 44 (2) , e66
Genetic variants in brain-derived neurotrophic factor associated with Alzheimer’s disease
Background: Alzheimer’s disease is complex, with variants in multiple genes contributing to interactions increasing risk for the disease. Brain-derived neurotrophic factor (BDNF) promotes neuronal survival and modulates hippocampal-dependent memory. Methods: We examined 11 SNPs that spanned the gene on chromosome 11p14 in 220 Alzheimer’s patients and 128 control spouses. Results: Not all of the SNPs were informative, due to minor allele frequencies of Conclusion: The combination of the diplotypes for three SNPs exhibited significant p values for Alzheimer’s APOE 4 non-carriers. The two SNPs (rs11030104 and rs2049045) are found between exons VI and VII, while the Val66Met polymorphism is located in the coding exon VIII; the total distance for the three SNPs is 14308 bp. Whether the SNPs are involved with alternative splicing of the VII/VIII transcript is of considerable interest.
- 1 August 2006
- Published by BMJ in Journal of Medical Genetics
- Vol. 43 (8) , e42
CYP19 haplotypes increase risk for Alzheimer’s disease
Cytochrome P450 aromatase, an enzyme that catalyses the conversion of androgens to oestrogen, is expressed at high levels in the gonads and in the brain. Aromatase activity is increased in the nucleus basalis of Meynert during aging and in Alzheimer’s disease (AD), making the gene (CYP19), at 15q21.1, a potential candidate risk factor.We examined 18 single nucleotide polymorphisms spanning the 5′-untranslated region and the entire coding region of CYP19 in 227 patients with AD and 131 control spouses.We found that the gene region could be divided into two haplotype blocks; a haplotype in block 1 and a haplotype in block 2 increased the risk of developing the disease by twofold in APOE 4 carriers. The implication of two haplotypes conferring increased risk for AD warrants further investigation of the regulation of aromatase activity in brain.
- 1 August 2006
- Published by BMJ in Journal of Medical Genetics
- Vol. 43 (8) , e42
CYP19 haplotypes increase risk for Alzheimer’s disease
Cytochrome P450 aromatase, an enzyme that catalyses the conversion of androgens to oestrogen, is expressed at high levels in the gonads and in the brain. Aromatase activity is increased in the nucleus basalis of Meynert during aging and in Alzheimer’s disease (AD), making the gene (CYP19), at 15q21.1, a potential candidate risk factor.We examined 18 single nucleotide polymorphisms spanning the 5′-untranslated region and the entire coding region of CYP19 in 227 patients with AD and 131 control spouses.We found that the gene region could be divided into two haplotype blocks; a haplotype in block 1 and a haplotype in block 2 increased the risk of developing the disease by twofold in APOE 4 carriers. The implication of two haplotypes conferring increased risk for AD warrants further investigation of the regulation of aromatase activity in brain.
- 1 February 2005
- Published by BMJ in Journal of Medical Genetics
- Vol. 42 (2) , 129-131
Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease
Background: Multiple genes have been provisionally associated with Alzheimer’s disease, including the coding polymorphisms in exons 8 and 13 in the low density lipoprotein receptor gene (LDLR), situated on chromosome 19p13.2. Methods: The sample groups consisted of 180 AD patients and 141 control spouses. We carried out genotyping of LDLR8 and LDLR13. Results: The LDLR8 GG genotype was common, found in 84% of the unaffected control subjects and 91% of the AD patients in our study. There was a ninefold elevation in risk associated with GG:CC versus A– and T– among APOE4+ subjects when compared with APOE4− subjects (odds ratio 9.3; 95% confidence interval 1.8 to 48.2). With the additional information on LDLR polymorphism, we defined an overall 12 fold elevation in risk for APOE4 in combination with LDLR GG:CC (11.9; 2.8 to 50.0; Fisher’s exact test, p = 0.0002; standard power 0.999), compared with other subjects lacking all three of these polymorphisms. Conclusion: These results imply a functional interaction between ApoE and LDL receptor proteins that determines risk for Alzheimer’s disease.
- 1 February 2005
- Published by BMJ in Journal of Medical Genetics
- Vol. 42 (2) , 129-131
Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease
Background: Multiple genes have been provisionally associated with Alzheimer’s disease, including the coding polymorphisms in exons 8 and 13 in the low density lipoprotein receptor gene (LDLR), situated on chromosome 19p13.2. Methods: The sample groups consisted of 180 AD patients and 141 control spouses. We carried out genotyping of LDLR8 and LDLR13. Results: The LDLR8 GG genotype was common, found in 84% of the unaffected control subjects and 91% of the AD patients in our study. There was a ninefold elevation in risk associated with GG:CC versus A– and T– among APOE4+ subjects when compared with APOE4− subjects (odds ratio 9.3; 95% confidence interval 1.8 to 48.2). With the additional information on LDLR polymorphism, we defined an overall 12 fold elevation in risk for APOE4 in combination with LDLR GG:CC (11.9; 2.8 to 50.0; Fisher’s exact test, p = 0.0002; standard power 0.999), compared with other subjects lacking all three of these polymorphisms. Conclusion: These results imply a functional interaction between ApoE and LDL receptor proteins that determines risk for Alzheimer’s disease.
- 10 April 2002
- Published by Wiley in American Journal of Medical Genetics
- Vol. 110 (1) , 30-35
Lack of association of the two polymorphisms in alpha-2 macroglobulin with Alzheimer disease
- 10 April 2002
- Published by Wiley in American Journal of Medical Genetics
- Vol. 110 (1) , 30-35
Lack of association of the two polymorphisms in alpha-2 macroglobulin with Alzheimer disease